Neumora Therapeutics (NASDAQ:NMRA) Posts Earnings Results, Hits Expectations

Neumora Therapeutics (NASDAQ:NMRA) announced its quarterly earnings results on Tuesday. The company reported ($0.34) EPS for the quarter, meeting the consensus estimate of ($0.34), Briefing.com reports.

Neumora Therapeutics Stock Performance

Neumora Therapeutics stock traded down $0.38 during mid-day trading on Wednesday, hitting $9.43. 88,593 shares of the company were exchanged, compared to its average volume of 477,181. Neumora Therapeutics has a 1-year low of $8.82 and a 1-year high of $21.00. The business has a fifty day moving average of $13.32 and a 200 day moving average of $14.08.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. William Blair reiterated an “outperform” rating on shares of Neumora Therapeutics in a research note on Friday, April 12th. Royal Bank of Canada reiterated an “outperform” rating and issued a $31.00 price objective on shares of Neumora Therapeutics in a report on Thursday, March 28th. Finally, JPMorgan Chase & Co. upped their price target on shares of Neumora Therapeutics from $20.00 to $22.00 and gave the company an “overweight” rating in a report on Monday, March 18th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Neumora Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $22.57.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.